Wave Life Sciences Q2 net loss $69.4M; WVE-007 Phase 2a dosing underway; FDA meeting for WVE-006

Wave Life Sciences Ltd.

Net loss $69.4M vs $50.5M YoY; revenue $2.3M vs $8.7M; cash $490.6M, runway into 3Q 2028.
WVE-007 (obesity) Phase 2a multidose dosing underway in BMI 35-50; combo/maintenance trials on track for 2H 2026.
FDA meeting scheduled for end of summer 2026 to discuss accelerated approval for WVE-006 (AATD).
WVE-008 (PNPLA3) CTA filing on track for 2H 2026; partnering discussions for HD and DMD programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.